DENVER, CO, June 25 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH. PK) (http://www.mitcanada.ca http://www.mitinvest.ca), MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners and a new order of 200 units. This private investment from our partners was done based on two issuances; the first for a total of US$ 250,000 at $ 0.10 and the second US$ 250,000 at $ 0.14. This investment and the new order show the beginning of a strong commitment and a step towards a successful long-term relationship between MIT and its Chinese partners.
Jiangsu Hualan MIT Medical Technology (MIT CHINA) Ltd., is actively promoting and selling MIT's unique Agro-Jet(R) needle-free jet injector for animal application, and Med-Jet(R) for human application, and is in the process of obtaining the certification for the production and sales of both models.
With the recent deaths from the outbreak of the "swine-flu" H1-N1 and the increased fear of the possible pandemic that could affect millions of people around the world, MIT and MIT China will be strongly promoting the Med-Jet(R) and the Agro-Jet(R) to help the world deal safely and efficiently with any decision that will be taken by governments for mass vaccination of humans and animals.
The MIT China venture is the beginning of a few Joint Venture agreements to be negotiated within the next several years. MIT is on its way to becoming a world leader in needle-free technology and its objective is to ensure that MIT injectors become an indispensable, environmentally friendly product for doctors and users around the world.
Medical International Technology Inc. is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to bot
Page: 1 2 Related biology technology :1
|SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.|
Copyright©2009 PR Newswire.
All rights reserved
. Concerned Shareholders of Biovail Pleased with Court Order for Biovail AGM2
. BIO Ventures for Global Health Announces Management Changes3
. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy4
. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program5
. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology6
. Healthy Advice Networks Announces Improved Patient Outcomes in Physicians Offices with Healthy Advice Programs7
. Spherix Announces Termination of Arla License Agreement8
. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose9
. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy10
. Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)11
. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration